SMI Presentation Offers Plant Sourced Surgical Bleeding Solution.

SAN JOSE, Calif. - SMI (Starch Medical Inc.) is pleased to announce participation at the European Association of Cardio-Thoracic Surgeons congress (www.eacts.org/) in Vienna, 18-21 October to showcase their advanced PerClot® Chinese manufactured hemostatic products. SMI is currently seeking further representation in select markets within the EU (lang@starchmedical.com), Asia-Pacific and Middle East (phil@starchmedical.com) for PerClot, and welcome enquiries at their EACTS booth number 56.

An SMI Marketing Partners Conference will also be conducted on Sunday, 18 October at 19:00. The Conference will include a clinical review of PerClot® applications and new product developments.

About SMI.

SMI (Starch Medical Inc.) is a San Jose, CA based medical device company engaged in the design, manufacture and sale of innovative, absorbable surgical hemostats synthesized from Absorbable Modified Polymers (AMP™), a proprietary, patent pending technology. SMI has organized a global distribution network for the marketing and sales of PerClot® Polysaccharide Hemostatic System (PHS), which launched in the 4th Quarter, 2008.

About AMP Technology.

Absorbable Modified Polymer (AMP™) technology is a proprietary engineering process that modifies plant starch into ultra-hydrophilic, adhesive forming hemostatic polymers. AMP™ materials are biocompatible, absorbable polysaccharides containing no animal or human components. Utilizing this purified plant source material is critical to minimizing the risks of infection and bleeding-related complications during surgery.
AMP™ particles have a molecular structure that rapidly absorbs water from blood, creating a high concentration of platelets, red blood cells and coagulation proteins at bleeding site, which accelerates the physiologic clotting cascade. The AMP™ blood interaction rapidly produces a gelled matrix that adheres to and forms a mechanical barrier with the bleeding tissue. AMP™ particles are readily dissolved by saline irrigation and are totally absorbed within several days.

StarFoam Pad from SMI

Starch Medical Inc. have released new footage of their StarFoam plant based hemostatic pad.

SMI came to market with a second generation of plant-based hemostatic solutions which contain no animal or human components in Q4 '08. Their first product, PerClot which has similarities to Medafor's manufactured Arista A.K.A. Hemostase MPH (Cryolife) and Vitasure (Orthovita), is currently sold in European and OUS Markets. The Starfoam product is a wafer-like pad which may be trimmed to suit the surgical procedure. StarFoam utilizes the same AMP technologies as all SMI products and is indicated for a wide range of applications, including but not limited to sternal edge bleeding and unique wound contours. CE mark for StarFoam was awarded in December, 2008.

Company President Mr David Lang comments "I encourage your cost-free evaluation of our innovative hemostatic and woundcare systems. A simple request at info@starchmedical.com will fulfill your product delivery and assure the presence of a Starch Medical representative."

Starch Medical Launches New, Bioinert Surgical Hemostats

SAN JOSE, Calif., Dec. 2 /PRNewswire/ -- Starch Medical Inc, a San Jose, CA-based medical device manufacturer, announces the CE approval of its PerClot(TM) Polysaccharide Hemostatic System (PHS) and the StarFoam(TM) Absorbable Polysaccharide Hemostat. Introduction of PerClot(TM) PHS will commence this month in the European Union and other select international markets. The StarFoam(TM) Absorbable Polysaccharide Hemostat will launch during the 2nd quarter, 2009.
PerClot(TM) PHS is an absorbable, surgical hemostat composed of Absorbable Modified Polymers (AMP(TM)). AMP(TM) technology incorporates sophisticated, plant-based polymer modification processes that yield biocompatible, polysaccharide particles. There is no thrombin, collagen, or other human or animal components in AMP(TM) particles. A family of customized, single-use application instruments will enhance the delivery of AMP(TM) to the wound site for the control of capillary, venous and arterial bleeding in both open and minimally invasive surgical procedures.
The StarFoam(TM) Absorbable Polysaccharide Hemostat, also developed with AMP(TM) technology, is produced in a hemostatic foam (wafer) configuration. Application of StarFoam(TM) will feature a simple "press and release" technique.
David Lang, President of SMI, commented, "The clinical introduction of PerClot(TM) PHS and its proprietary, integrated AMP(TM) technology represents the next generation of polysaccharide hemostatic agents. The StarFoam(TM) product line will offer surgeons a choice of hemostatic formats for a range of surgical wounds. Compared to current polysaccharide based hemostats, PerClot(TM) PHS and StarFoam(TM) demonstrate superior hydrophilic action and enhanced adhesive strength. These performance features, coupled with custom delivery systems, have been favorably received in a diverse range of surgical applications in Europe, Asia and Latin America."
SMI is a privately-held medical device company engaged in the design, manufacture, marketing and licensing of breakthrough, hemostatic solutions. Starch Medical's proprietary, patent-pending technology platform (AMP(TM)), including powders, foams and films, will focus on the worldwide, multi-billion dollar biomaterial, hemostasis, and wound care marketplace. For additional information, distribution inquiries, and licensing options, visit http://www.starchmedical.com/.